Core Viewpoint - The Shanghai Institute of Immunology, affiliated with Shanghai Jiao Tong University School of Medicine, is recruiting for various research positions to enhance its research capabilities in antigen presentation and immune therapy, focusing on innovative breakthroughs and translational research [1][4]. Group 1: Institute Overview - Established in 1979, the Shanghai Institute of Immunology is the first immunology research institution in China, with 24 group leaders, including 12 from the National High-Level Talent Program and 3 recipients of the National Outstanding Youth Science Fund [1]. - The institute has published significant original research in top-tier journals such as Cell, Nature, and Science, contributing to internationally influential breakthroughs [1]. - The institute maintains close collaborations with nearly 50 renowned universities and research institutions globally, fostering international talent development [1]. Group 2: Research Focus - The research group focuses on antigen presentation, which is crucial for activating specific T cells and establishing immune surveillance, serving as a bridge between innate and adaptive immunity [3]. - The group aims to explore the regulatory mechanisms of antigen presentation in tumor cells and pathogens, which are key factors in immune therapy resistance [3][4]. - Research areas include classic antigen presentation mechanisms, cross-presentation by antigen-presenting cells (APCs), and the impact of the disease microenvironment on antigen presentation [4]. Group 3: Recruitment Positions - The institute is seeking to hire one Associate Researcher or Assistant Researcher, with requirements including a PhD from a top institution and postdoctoral experience in relevant fields [5]. - The recruitment also includes 2-3 postdoctoral positions, with candidates expected to have a strong research background and the ability to conduct independent research [8][9]. - Additionally, 2-3 research assistant internships are available for candidates with a passion for research and relevant academic achievements [12]. Group 4: Compensation and Benefits - Competitive salaries will be offered according to the policies of Shanghai Jiao Tong University and the Shanghai Institute of Immunology, with opportunities for career establishment [6]. - Postdoctoral candidates may receive a starting annual salary of 270,000 RMB, with potential for higher earnings through various incentive programs [10]. - The institute encourages participation in academic exchanges and supports researchers in applying for various funding and talent programs [7][11].

Core Viewpoint - The research on human M cells reveals their dual role in antigen transport and active antigen presentation, suggesting they may play a significant role in autoimmune diseases like celiac disease, thus providing new therapeutic targets and insights into intestinal mucosal immunity [2][26]. Group 1: Understanding M Cells - M cells are rare epithelial cells in the Peyer's patches of the intestine, traditionally viewed as specialized antigen transporters that deliver antigens to immune cells [8]. - The study led by Hans Clevers and Wang Daisong utilized human intestinal organoid technology to cultivate and analyze human M cells, uncovering their complex functions [11][13]. - Human M cells exhibit gene expression profiles similar to dendritic cells, indicating they can actively capture, process, and present antigens to T cells, thus acting as immune "activators" [15][16]. Group 2: Role in Celiac Disease - The research identified M cells as key players in celiac disease, where gluten proteins trigger an immune response [17][24]. - M cells were shown to process gluten antigens and present them via HLA-DQ2.5 molecules, leading to T cell activation [19][21]. - M cells also express transglutaminase 2 (TGM2), which modifies gluten proteins, enhancing their pathogenicity and contributing to the inflammatory response in celiac disease [24]. Group 3: Implications for Future Research - This study transforms the understanding of M cells and intestinal mucosal immunity, suggesting they are specialized antigen-presenting cells derived from epithelial sources [26]. - It opens avenues for developing targeted therapies for celiac disease and food allergies by focusing on M cell functions and TGM2 activity, potentially allowing for precise interventions without compromising overall immunity [26]. - The findings emphasize the need for careful consideration of species differences when translating mouse model research to human clinical applications [26].

Core Viewpoint - mRNA vaccines represent a transformative advancement in immunology, characterized by rapid production and strong immunogenicity across various disease conditions [3][4]. Group 1: mRNA Vaccine Technology - The use of lipid nanoparticles (LLN) has emerged as a versatile and efficient delivery vehicle, enhancing stability and adaptable surface chemistry for the development of effective and low-toxicity targeted mRNA vaccines [3]. - mRNA vaccines generate robust and long-lasting protective immunity, primarily through antigen-presenting cells (APC), particularly dendritic cells (DC), which efficiently present antigens and optimally localize to lymphoid tissues [4]. Group 2: Challenges in Vaccine Delivery - Direct targeting of dendritic cells significantly improves vaccine efficacy; however, non-specific uptake by macrophages during in vivo vaccine delivery poses a major challenge [4]. - Despite macrophages' phagocytic capabilities, their ability to transport antigens from peripheral tissues to lymphoid tissues for effective initial T cell stimulation is limited [4]. - Reducing macrophage-mediated uptake of nanoparticle vaccines is crucial for promoting lymph node transport and ultimately enhancing vaccine efficacy [4]. Group 3: Research Development - On August 18, 2025, a collaborative research paper titled "A precision-engineered dendritic cell-targeted mRNA nanovaccine for enhanced antiviral immunity" was published by teams from Sichuan University, led by Song Xiangrong and Liu Jiyan, in the journal Cell Biomaterials [4].